• 主页
  • 查找结果
  • Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Future oncology (London, England) (2013-11-15)
Nicoletta Colombo
摘要

Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

材料
货号
品牌
产品描述

Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂黑, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder, 99.995% trace metals basis
Sigma-Aldrich
铂, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
铂, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
铂, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.10 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, powder, ≤10 μm, 99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂黑, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.076 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.125-0.135 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Sigma-Aldrich
铂, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
铂, wire, diam. 0.127 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.20 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铂, wire, diam. 0.127 mm, 99.9% trace metals basis
Sigma-Aldrich
铂, powder (coarse), 99.99% trace metals basis
Sigma-Aldrich
铂黑, low bulk density, ≥99.9% trace metals basis
铂, wire reel, 0.1m, diameter 1.0mm, annealed, may be used as one component of a thermocouple, 99.99%
铂, wire reel, 1m, diameter 0.3mm, annealed, may be used as one component of a thermocouple, 99.99%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。